Tae Min Oh is an expert in the fields of bitcoin. He published Bitcoin Has Been Strong in 2014 and Smart Contracts: The Trust Revolution in 2017. He believes that the combination of genome and blockchain would expand the global supply chain finance. He is the head of MyGenomeBox’s Blockchain Management Research Institute and vice-president of MyGenomeBox.
“ GNC is free from regulations
The purpose of GNC generation is to create “DNA based open sharing ecosystem” which allows anyone to manage or improve their lifestyle using their own genome data. Individuals will be rewarded every time their genome data is used and be assured that their genome data will not be abused or accessed without their consent. Once meaningful amounts of genome data are collected, various sectors can come together to create a genome-based ecosystem. The ecosystem will attract both consumers offering their genome data and organizations from food, cosmetics, insurance, pharmaceuticals, medicine, research, and other areas.
"100 SNP related to genetic information"
Combining a user’s 100 genome data visualizes their traits and gives users the pleasure of discovering something new about themselves and expressing their genetic code in an avatar for gaming or social networks. The genetic avatar leads to a better understanding of the essential characteristics of family members and loved one, driving recommendations and adoption of colored coin making.
Create your own avatar with your 100 SNP related to genetic information. You can dress or dole up your avatar with accessory items. This avatar is your real alter ego to express yourself without exposing your actual appearance on any online activities! When presenting the avatar as a verifiable ID to a third party, specific texts plus trait values are also displayed; the name of genes and the frequency of phenotypes are shown in numbers.
Another useful application of coin coloring occurs when you encode multiple tokens with identical metadata. Issuing a limited number of tokens in this manner, containing a famous star’s genome information the “O.P.P.A. Token”, would allow its use in marketing activities while preventing any potential controversies over copyright as such tokens cannot be created without active consent from the star and/or their management agency. Fans may want to own a token containing the genome of their favorite stars. They can then personalize the avatar, even though the token is loaded with the same base information. As O.P.P.A. tokens are issued in limited numbers, scarcity makes them collectible, pushing up the value.
“UN Initiatives, ID22” is to create valid IDs for 1.1 billion people around the world who do not have any government issued record of their birth status.
with myGeNome colored coin, the amount of balance in one’s stock, bond or bank accounts can be attached to a certain amount of bitcoin and transferred to someone else. Unlike bitcoin, that has no intrinsic value, colored coin is a method for representing and tokenizing real-world assets. In addition to proving ownership of real-world assets such as real estate deeds or car keys, colored coin can also represent and verify college diplomas, transcripts or personal identification records. The United Nations acknowledged that blockchain is the only viable method available for authenticating personal identification papers presented by refugees.
GNC will serve as a catalyst for the genetic data ecosystem. But no matter how high the unit utility (benefit) to unit cost ratio becomes, the current genome sequencing market cannot reach equilibrium.
The market could reach equilibrium if genetic data owners are incentivized to share their information. This concept underlies the “sell your DNA” market approach. If economic incentives are not enough to motivate owners, then the call to action where users share in service of humanity and financial gain as provided by GNC may act as the catalyst needed for private subsidy of the public good from shared genome data.
MyGenomeBox has always focused on creating genetic information based management with all different industries to structure new industrial ecosystem. GNC generation is one of those activities to maximize the value of market participation and ensure transparent sovereignty of individual’s genetic information.
GNC are only used as an incentive for those that provide genomes for the public interest. Therefore, a connection for ecosystem is established where a virtuous profit is made between individuals and the public interest.
Our Team |
Jang Hong Choi is responsible for the development and management of Genome Coin. He has lots of experience in software development and he is making a significant contribution in stabilizing GNC ecosystem. He developed DMB system for Korea Broadcast System, LG Smartshare, UC messenger and video conference system.
Soheil, co-founder of 3 subsidiaries of The Blockchain Group, oversees the ecosystem’s operations and structuring of the company’s technical asset projects. As a blockchain advisor, Soheil employs his expertise and experience to work directly with businesses of all sector around the world.
Mack Fitt Pijewski is currently working as a Business Development for Prenetics, the leading genetic testing healthtech company in Southeast Asia. As a Business entrepreneur, Mack has honed his skills in Business and Fitness LifeStyle through years of varied training in commercial enterprise and athletic arena.
Our Team |
Our team is all about quality, craft and disciplined experimentation.
We are active contributors to create new eco-system for everyone pursue better lifestyle.
Dr. Seok-Cheol Baek is a Big Data expert. After earning his doctorate degree from KAIST, he has worked at multiple companies such as Linux Security, NIBD, and KT. He is now the Chief Technology Officer of MyGenomeBox®.
Young Tae (YT) Park, the CEO of MyGenomeBox, has an international background and education with service business operations as well as in fundamental design business in an abroad organization. YT is bringing positive difference to MyGenomeBox by operating effectively with various partners in a fully globalized environment.
Dr. Min Seob Lee, a global leader in genome research, diagnostic medicine and customized medicine, has a long history of research in the life sciences industry, including biotech companies and diagnostic medical companies. In particular, he is recognized for his expertise in the fields of genomics, pharmacogenomics, bioinformatics, and diagnostic development.
Mr. Shang Cheol Shin is the co-CEO of the EDGC. After graduating from Yonsei University, he joined Samsung Securities and has been involved with the wide range of business. Mr. Shin’s working experience in investment banking involves interaction with hundreds of companies, and he focused on IPO, M&A, privatization of the public corporation, and capital raises. He has an excellent understanding for various issues and solutions for corporations at various stages of their corporate life cycle.
Dr. Charles Cantor is co-founder, and Chief Scientific Officer at SEQUENOM, Inc., the leading provider of noninvasive parental testing. In the past decade, Charles has focused his attention on developing rational and cost-effective approaches to preventive and personalized medicine. He held academic and leadership positions at Columbia and several other distinguished American universities.
Dr. Geordie Rose founded D-Wave, the world’s first quantum computing company, and Kindred, the world’s first robotics company to use reinforcement learning in a production environment. He cooperated with Google, NASA, Lockheed Martin, and several US government agencies. Currently, he is trying to solve the AGI problem at Sanctuary, the leading company in the AI sector.
Dr. Stefan Gruenwald the President of Diagnomics. His career in life science spans more than two decades and he holds three patents, based on technologies developed at PharMingen. He is also an initiator of popular Science Newsletter with over 300,000 reads. He has broad scientific knowledge in many disciplines, including Biotechnology and Nanotechnology.
Dr. Carlotta Glackin is an Associate Professor and member of the Women’s Cancers and Molecular Cellular Biology of Cancer (MCBC) Programs at the City of Hope Comprehensive Cancer Center (COHCCC). Her research has focused primarily on the functional role of elevated TWIST expression in cancer cells.
Mr. Dan Scholefield is a co-founder of Diagnomics and is currently taking on the role as CFO and Chairman of the Board. He serves as a trustee, managing several private family office operations with a tenure that spans over 20 years. He is also a principal at Three Layer Capital. He brings an experience level and successful investment track record that includes leading due diligence efforts, closing deals and managing investment ventures in various technologies.
Michael O’Reilly’s Genomics Personalized Health (GPH) facilitates access to the world’s most advanced Whole Genome Sequencing service performed at CLIA certified and CAP accredited laboratories located within the United States. GPH empowers individuals with their genomic data as the baseline for preventative wellness and lifestyle applications informed by science.